SL Science Holding Ltd
SL Science Holding Ltd is a U.S.-listed biotechnology and biological products company based in Taipei, Taiwan, operating through its SL Bio business. It develops and commercializes exosome-based skincare and haircare products and is also building a pipeline around licensed cell therapy and related life-science technologies.
Business
Share of revenueSkincare and haircare products sold under SL Science's branded exosome portfolio.
Wholesale and distribution sales of exosome products to corporate customers and partners.
Development rights and related services tied to CD-19 Armed-T and GDT cell therapy assets.
Support activities, documentation preparation, and technical services linked to licensed programs.
Customers
The company sells mainly to consumers through skincare and haircare channels, and to corporate customers that distribute or market its exosome products. It also works with licensing and development partners in cell therapy, where counterparties fund or milestone-support specific technologies. Demand is tied to premium beauty, regenerative health, and biopharma development use cases.
Buy exosome skincare and haircare products for anti-aging and regenerative benefits.
Purchase branded products for resale and market coverage in Asia.
Enter licensing and collaboration arrangements around Armed-T and GDT assets.
Use technical support and product training tied to corporate distribution or development programs.
Strategy
The company is building a two-track model: branded exosome products for consumer and corporate channels, and licensed cell-therapy assets for longer-dated value creation. Its strategy centers on expanding Asian distribution, strengthening partner-led commercialization, and advancing regulated therapeutic programs toward clinical milestones. Scaling production, channel reach, and licensed intellectual property are central to its competitive position.
Broader channel coverage can lift product reach and reduce reliance on retail sales.
Clinical progress can unlock licensing value and future commercialization options.
Future revenues depend on the duration and performance of licensed technology agreements.
Geography
The business is centered in Taiwan, where the company is headquartered and where exosome sales to corporate customers have been disclosed. It also uses distribution arrangements to promote branded products across Asia, making regional channel access an important part of the model. The company is incorporated in the United States and accesses U.S. capital markets, while its commercial footprint remains Asia-focused.
Risks
The business depends on a single exosome supplier in Taiwan, licensed technology partners, and regulatory outcomes for its therapeutic pipeline. It also faces execution risk from clinical development, milestone obligations, and the need to scale specialized manufacturing and technical capabilities. As a biotech and biological-products business, commercialization timing, product acceptance, and reimbursement or regulatory clearance can materially affect future performance.
- Single-supplier concentrationImpact: HighLikelihood: High
Exosome product costs and availability depend on one supplier in Taiwan, limiting bargaining power and resilience.
Exposure: Exosome products
- Regulatory approval uncertaintyImpact: HighLikelihood: High
The company has no FDA-approved products and therapeutic programs must clear nonclinical and IND hurdles.
Exposure: Armed-T and GDT pipeline
- License milestone paymentsImpact: HighLikelihood: Medium
Future cash outflows depend on achievement of development milestones under licensing agreements.
Exposure - Clinical and development failureImpact: HighLikelihood: Medium
Early-stage cell therapy assets may not produce successful data or regulatory progress.
Exposure: GDT and Armed-T programs
Accounting
Judgemental itemsSales through retail, corporate distribution, and licensed services may be recognized at different points in time.
Impact: Affects quarterly revenue timing and comparability
License agreements include future payments contingent on technical and regulatory events.
Impact: Creates estimate-based liabilities and future cash outflows
The company disclosed substantial doubt about continuing as a going concern.
Impact: Important for valuation, liquidity assessment, and disclosure risk
Contracted development obligations and services can create accruals before commercialization.
Impact: Affects expenses, liabilities, and cash planning
Similar listed companies
Publicly listed companies with a comparable business focus.
Yubo International Biotech Ltd
YBGJ · Electromedical & Electrotherapeutic Apparatus
Yubo International Biotech Ltd is a U.S.-listed holding company whose operating business is conducted in China through Yubo International Biotech (Beijing)…
Jyong Biotech Ltd.
MENS · Pharmaceutical Preparations
Longevity Health Holdings, Inc.
XAGEW · Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics
eXoZymes Inc
EXOZ · Biological Products, (No Diagnostic Substances)
YD Bio Ltd
YDES · Services-Medical Laboratories
YD Bio Ltd is a U.S.-anchored biotechnology and medical-laboratory services company with operations spanning regulated diagnostics, life science clinical…
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Last updated: 28/09/2026